Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Lfb Biotechnologies

Université De Limoges

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique-cnrs

Mab Factory Gmbh

Labortoire Francais Du Fractionnement Et Des Biotechnologies

Laboratoire Francais Du Fractionnement Et Des Biotechnolgies (lfb)

Laboratoire Francais Du Fractionnement Et Des Biotechnologies Societe Anonyme

Christophe De Romeuf

Emmanuel Nony

Nicolas Bihoreau

Dominique Bourel

Roland Beliard

Christine Gaucher

Arnaud Glacet

Sylvie Jorieux

Philippe Klein

Amaud Glacet

Alexandre Fontayne

Jean-luc Teillaud

Christian Behrens

Philippe Mondon

Christophe Sirac

Jean-Claude Brouet

Nathalie Fournier

Abdessatar Chtourou

Wolf Herman Fridman

Lars Toleikis

Stefan Dübel

Michael Hust

Frédéric Dhainaut

Jean-François Prost

Holger Thie

Céline Monnet

Jacky Lirochon

Arnaud Clacet

Sophie Siberil

Thomas Schirrmann

Céline Monnet-Mars

Jean-Francois Prost

Jean-Luc Teillaud

Nicholas Bihoreau

Christine Gauchet

Roland Belliard

The present invention relates to a chimeric protein comprising at least one human amyloid P component and at least one fragment of an Fc region of a human antibody, the human amyloid P component and the fragment of an Fc region with which it is associated being bound to each other by means of a hinge region.

Chimeric protein in the treatment of amyloidosis

The present invention relates to the use of antibody Fc fragments in the treatment of autoimmune and/or inflammatory diseases, said Fc fragments being isolated recombinant Fc fragments having a modified affinity for at least one of the Fc receptors (FcR), particularly an increased affinity to FcRn.

Use of modified Fc fragments in immunotherapy

Disclosed is to a polypeptide including a mutated Fc region and having functional activity, mediated by the Fc region, that is modified compared with that of a parent polypeptide. The Fc region includes at least one combination of 2 mutations, the combination being selected from among one mutation selected from among a first set of mutations, and at least one mutation selected from among a second set of mutations, and provided that mutation (i) does not take place on the same amino acid as mutation (ii). Also disclosed are use of the polypeptide, compositions including the same, and methods for preparing the polypeptide.

Fc mutants with modified functional activity

The invention relates to chimeric or humanised anti-CD303 antibodies to nucleic acids coding for the heavy and light chains of these antibodies, expression vectors, host cells, transgenic non-human animals or transgenic plants expressing said antibodies, as well as to the uses thereof in the treatment or prevention of blastic plasmacytoid dendritic cell neoplasms (BPDCN) or inflammatory diseases, in particular autoimmune diseases, involving plasmacytoid dendritic cells.

Anti-CD303 monoclonal antibodies

The invention relates to a cell line expressing the gamma chain of the Fc&#x3b5;RI receptor and human CD303 antigen, characterized in that said cell line is transfected in a stable manner by an expression vector comprising a nucleic acid molecule coding for human CD303 antigen and having strong expression of human CD303 on the surface thereof, e.g. at least 10000 molecules of human CD303 per cell, as well as a vector or vector kit that can be used to co-express the gamma chain of the Fc&#x3b5;RI receptor and human CD303 antigen, and different uses of the cell line of the invention.

Cell line overexpressing human CD303 antigen

The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for hemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP).

Monoclonal antibodies with enhanced ADCC function

The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.

Use of ADCC-optimized antibodies for treating low-responder patients

The present invention relates to a monoclonal antibody method directed against CD20 antigen including administration of an anti CD20 antibody wherein each of the light chains thereof has the murine-human chimeric amino acid sequence SEQ ID NO: 28, and each of the heavy chains thereof has the murine-human chimeric amino acid sequence SEQ ID NO: 20.

Antibody method for treatment of a disease in which the target cells are cells which express CD20

The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADCC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).

The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADCC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for hemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).

The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP).

Antibodies having a high specificity and high affinity towards the human gene product MUC1, which in specific variants is associated with neoplastic cells, i.e. tumor tissue, to the use of the antibodies for medical purposes, i.e. for tumor treatment, and for analytical purposes, e.g. for tumor diagnosis. Compositions comprising the antibodies, e.g. for use in the analytical processes and analysis, to pharmaceutical compositions comprising the antibodies, and to use of the antibodies in the manufacture of pharmaceutical compositions for tumor treatment or for diagnostic purposes.

Recombinant anti-MUC1 antibodies

The invention is directed to a monoclonal antibody directed against CD20 antigen, for therapeutic administration to humans, wherein each of the light chains of the antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 27, and each of the heavy chains of the antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 19. The invention is further directed to methods of in vitro activation of Fc&#x3b3;RIIIA receptors in immune effector cells with the antibody and methods of treating CD20-expressing leukaemia or lymphoma with the antibody.

Monoclonal antibody directed against CD20 antigen

Use of ADCC-optimized antibodies for treating weak patients

Growing community of inventors

Lambersart, France

Christophe De Romeuf